

Not for distribution or release in the United States or to U.S. persons

ASX Announcement

24th January 2024

GENETIC SIGNATURES SUCCESSFULLY COMPLETES UNDERWRITTEN RIGHTS ISSUE

On Thursday, 21 December 2023, Genetic Signatures Limited (ASX:GSS), an Australian-based global molecular diagnostics company (**Genetic Signatures** or the **Company**) announced a placement to new and existing sophisticated and professional investors (**Placement**) together with a fully underwritten pro-rata non-renounceable entitlement offer of 1 New Share for every 6.65 existing fully paid ordinary shares in the Company (**Rights Issue**). Under the Placement and Rights Issue (**Capital Raising**), the Company raised total proceeds of approximately \$15.9 million before costs.

Today Genetic Signatures is pleased to announce the successful completion of the Rights Issue. The Rights Issue allowed eligible shareholders in the Company (**Eligible Shareholders**) the opportunity to subscribe for 1 New Share for every 6.65 existing fully paid ordinary shares which they held in Genetic Signatures as at 7.00pm (Sydney, Australia time) on Thursday 28 December 2023 at a price of \$0.37 per New Share.

The Rights Issue closed at 5.00pm (Sydney time) on Thursday 18 January 2024 with valid applications for entitlements received raising approximately \$6.9 million. Total eligible applications under the Rights Issue Offer represents a take-up rate of 86.8%. The shortfall after the issue of New Shares from the Rights Issue, being approximately \$1.1 million, will be allocated to the underwriters of the Rights Issue. The shortfall is comprised of entitlements not taken up by Eligible Shareholders.

The issue of New Shares is scheduled to occur on Thursday, 25 January 2024, with those shares expected to commence trading on the ASX on Monday, 29 January 2024. New Shares issued under the Rights Issue will rank equally in all respects with existing ordinary shares on issue with effect from their date of issue.

Bell Potter Securities Limited and Taylor Collison Limited (**Joint Lead Managers** or the **Underwriters**) are acting as joint lead managers to the Capital Raising and underwriters to the Rights Issue pursuant to a lead mandate letter and underwriting agreement.

Eligible Shareholders should confirm the actual number of New Shares issued to them before trading in such shares, and the sale by any Eligible Shareholder of New Shares prior to receiving their holding statement is at their own risk.

Funds raised under the Capital Raising will be used for additional regulatory approvals, new customer installations, next generation Instrument development and new product development, general working capital and the costs of the Capital Raising.

The board of Genetic Signatures wishes to thank all Eligible Shareholders who participated in the Rights Issue.

– ENDS –

Authorisation and Additional Information

This announcement was authorised by the Board of Directors of Genetic Signatures Limited.

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Dr John Melki
Managing Director and
Chief Executive Officer
john.melki@geneticsignatures.com
T: +61 (0)2 9870 7580

Karl Pechmann
Chief Financial and Operating Officer
and Company Secretary
karl.pechmann@geneticsignatures.com

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base®**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen™* brand. Genetic Signatures' proprietary MDx **3base®** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its *EasyScreen™* respiratory kits and the growing interest in its gastroenteritis products to further commercialise its **3base®** technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.